STTR Phase I: Aptamer Biosensors with the Longevity and Technology Compatibility Required for Continuous Biosensing Devices Beyond Glucose

STTR 第一阶段：适体生物传感器具有葡萄糖以外的连续生物传感设备所需的寿命和技术兼容性

• 批准号: 2212221
• 负责人: Aleksandar Karajic
• 金额: $ 25.59万
• 依托单位: KILELE HEALTH LLC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-06-15 至 2023-09-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2212221&HistoricalAwards=false
• 关键词: STTR; Phase; Aptamer; Biosensors; Longevity

The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase I project is to improve clinical outcomes for patients with wearable biosensor needs. This project will develop wearable continuous glucose biosensor platforms to address a broad set of disease and wellness applications, such as measuring additional molecules relevant to diabetes management, improving management of cardiovascular diseases, and therapeutic drug monitoring to customize dosages. In addition to impacting human health (particularly for chronic diseases) in the United States, the commercial market is significant and valued at approximately $120 B/year. Furthermore, these biosensors will provide data directly to patients to inform their decisions. This Small Business Technology Transfer (STTR) Phase I project will address the limitations which have prevented continuous diagnostic monitoring platforms from adding clinical utility beyond sensing glucose with enzymatic sensors. Unlike enzymatic glucose sensors, electrochemical aptamer sensors are rapidly adaptable to measuring other molecules in the body with high specificity and sensitivity. However, aptamer sensors currently degrade rapidly in live animals (6-12 hours) and must be inserted through a highly-invasive incision. This STTR Phase I project will demonstrate robust and longer-lasting functioning of aptamer biosensors in a real biofluid environment. It will use a software-enabled method in which only one electrode is inserted, making the resulting device truly minimally invasive.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这个小企业技术转让（STTR）第一阶段项目的更广泛的影响/商业潜力是改善具有可穿戴生物传感器需求的患者的临床结果。 该项目将开发可穿戴式连续葡萄糖生物传感器平台，以解决广泛的疾病和健康应用，例如测量与糖尿病管理相关的其他分子，改善心血管疾病的管理，以及治疗药物监测以定制剂量。 在美国，除了影响人类健康（特别是慢性疾病）之外，商业市场也很重要，价值约为120 B美元/年。 此外，这些生物传感器将直接向患者提供数据，以告知他们的决定。该小型企业技术转让（STTR）第一阶段项目将解决限制连续诊断监测平台在使用酶传感器检测葡萄糖之外增加临床实用性的问题。与酶促葡萄糖传感器不同，电化学适体传感器可快速适应于以高特异性和灵敏度测量体内的其他分子。然而，适体传感器目前在活体动物中迅速降解（6-12小时），并且必须通过高度侵入性的切口插入。 该STTR第一阶段项目将展示适体生物传感器在真实的生物流体环境中的强大和持久的功能。该奖项反映了NSF的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。